Please use this identifier to cite or link to this item:
|Title:||Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.|
|Authors:||Herbertson, Rebecca A;Tebbutt, Niall C;Lee, Fook-Thean;MacFarlane, David J;Chappell, Bridget;Micallef, Noel;Lee, Sze-Ting;Saunder, Timothy;Hopkins, Wendie;Smyth, Fiona E;Wyld, David K;Bellen, John;Sonnichsen, Daryl S;Brechbiel, Martin W;Murone, Carmel;Scott, Andrew M|
|Affiliation:||Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia.|
|Citation:||Clinical Cancer Research : An Official Journal of the American Association For Cancer Research 2009; 15(21): 6709-15|
|Abstract:||This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Le(y) antigen.The primary objectives were to determine biodistribution and pharmacokinetics of CMD-193. Secondary objectives included response rates and change in tumor metabolism. Patients with progressive, measurable, and Le(y) positive malignancies were eligible for enrollment in one of two dose cohorts, 1.0 and 2.6 mg/m(2). The first cycle was trace labeled with (111)In for biodistribution assessment using gamma camera imaging. Subsequent cycles were administered every 3 weeks up to a maximum of six cycles, depending on toxicity and response. Pharmacokinetic analysis was based on radioassay and ELISA.Nine patients were enrolled in the study. Biodistribution images showed initial blood pool activity, followed by markedly increased hepatic uptake by day 2, and fast blood clearance in all patients. There was low uptake in tumor in all patients. The overall T(1/2)beta of (111)In-CMD-193 was 102.88 +/- 35.67 hours, with no statistically significant difference between the two dose levels. One patient had a partial metabolic response on (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG PET) after four cycles, but no radiological responses were observed. Myelosuppression and effects on liver function were the most significant adverse effects.CMD-193 shows rapid blood clearance and increased hepatic uptake compared with prior studies of the parental antibody hu3S193. These results highlight the importance of biodistribution and pharmacodynamic assessment in early phase studies of new biologics to assist in clinical development.|
|Internal ID Number:||19825951|
Antibodies, Monoclonal.therapeutic use
Antibodies, Monoclonal, Humanized
Immunoconjugates.administration & dosage.adverse effects.metabolism.pharmacokinetics
Lewis Blood-Group System.immunology
Neoplasms, Glandular and Epithelial.drug therapy
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.